Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF^V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clin Cancer Res (2021) 27 (19): 5225–5235.

https://doi.org/10.1158/1078-0432.CCR-21-0809

Published: 01 October 2021

View article titled, 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Journal Articles

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Ornella Cutaia, Giovanni Amato, Alessia Covre, Roberto Camerini, Luana Calabrò, Monica Valente, Diana Giannarelli, Mario Mandalà, Michele Maio

Clin Cancer Res (2021) 27 (17): 4737–4745.

https://doi.org/10.1158/1078-0432.CCR-21-1046

Published: 01 September 2021

View article titled, Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Includes: Supplementary data

Journal Articles

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, Anna Maria Di Giacomo

Clin Cancer Res (2020) 26 (16): 4201–4205.

https://doi.org/10.1158/1078-0432.CCR-20-1657

Published: 14 August 2020

View article titled, Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Journal Articles

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Clin Cancer Res (2019) 25 (24): 7351–7362.

https://doi.org/10.1158/1078-0432.CCR-19-1335

Published: 13 December 2019

View article titled, Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Includes: Supplementary data

Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF^V600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas

Clin Cancer Res (2019) 25 (11): 3239–3246.

https://doi.org/10.1158/1078-0432.CCR-18-0720

Published: 01 June 2019

View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Includes: Supplementary data

Journal Articles

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Clin Cancer Res (2017) 23 (8): 1929–1936.

https://doi.org/10.1158/1078-0432.CCR-16-1272

Published: 13 April 2017

View article titled, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Includes: Supplementary data

Journal Articles

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Clin Cancer Res (2016) 22 (22): 5487–5496.

https://doi.org/10.1158/1078-0432.CCR-16-0127

Published: 14 November 2016

View article titled, Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Includes: Supplementary data

Journal Articles

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Clin Cancer Res (2016) 22 (12): 2908–2918.

https://doi.org/10.1158/1078-0432.CCR-15-2412

Published: 14 June 2016

View article titled, Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Includes: Supplementary data

Journal Articles

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Michele Maio, Alessia Covre, Elisabetta Fratta, Anna Maria Di Giacomo, Pietro Taverna, Pier Giorgio Natali, Sandra Coral, Luca Sigalotti

Clin Cancer Res (2015) 21 (18): 4040–4047.

https://doi.org/10.1158/1078-0432.CCR-14-2914

Published: 14 September 2015

View article titled, Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Journal Articles

Circulating CD4⁺ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

Henning Zelba, Benjamin Weide, Alexander Martens, Evelyna Derhovanessian, Jithendra Kini Bailur, Christina Kyzirakos, Annette Pflugfelder, Thomas K. Eigentler, Anna Maria Di Giacomo, Michele Maio, Erik H.J.G. Aarntzen, Jolanda de Vries, Antje Sucker, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec

Clin Cancer Res (2014) 20 (16): 4390–4399.

https://doi.org/10.1158/1078-0432.CCR-14-1015

Published: 13 August 2014

View article titled, Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

Includes: Supplementary data

Journal Articles

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

Benjamin Weide, Alexander Martens, Henning Zelba, Christina Stutz, Evelyna Derhovanessian, Anna Maria Di Giacomo, Michele Maio, Antje Sucker, Bastian Schilling, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec

Clin Cancer Res (2014) 20 (6): 1601–1609.

https://doi.org/10.1158/1078-0432.CCR-13-2508

Published: 13 March 2014

View article titled, Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

Includes: Supplementary data

Journal Articles

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Clin Cancer Res (2012) 18 (23): 6485–6496.

https://doi.org/10.1158/1078-0432.CCR-12-1516

Published: 29 November 2012

View article titled, Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Includes: Supplementary data

Journal Articles

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

Clin Cancer Res (2011) 17 (10): 3064–3076.

https://doi.org/10.1158/1078-0432.CCR-10-2234

Published: 15 May 2011

View article titled, Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

Journal Articles

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O'Day, Jeffrey S. Weber, Omid Hamid, Celeste Lebbé, Michele Maio, Michael Binder, Oliver Bohnsack, Geoffrey Nichol, Rachel Humphrey, F. Stephen Hodi

Clin Cancer Res (2009) 15 (23): 7412–7420.

https://doi.org/10.1158/1078-0432.CCR-09-1624

Published: 30 November 2009

View article titled, Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Includes: Supplementary data

Journal Articles

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Ester Fonsatti, Hugues J.M. Nicolay, Luca Sigalotti, Luana Calabrò, Laura Pezzani, Francesca Colizzi, Maresa Altomonte, Massimo Guidoboni, Francesco M. Marincola, Michele Maio

Clin Cancer Res (2007) 13 (11): 3333–3338.

https://doi.org/10.1158/1078-0432.CCR-06-3091

Published: 01 June 2007

View article titled, Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Journal Articles

The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma

Annette Paschen, Norbert Arens, Antje Sucker, Karin M. Greulich-Bode, Ester Fonsatti, Annunziata Gloghini, Sandra Striegel, Nicole Schwinn, Antonino Carbone, Ralf Hildenbrand, Adelheid Cerwenka, Michele Maio, Dirk Schadendorf

Clin Cancer Res (2006) 12 (11): 3297–3305.

https://doi.org/10.1158/1078-0432.CCR-05-2174

Published: 01 June 2006

View article titled, The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma

Journal Articles

Heat Shock Proteins and Their Use as Anticancer Vaccines

Giorgio Parmiani, Alessandro Testori, Michele Maio, Chiara Castelli, Licia Rivoltini, Lorenzo Pilla, Filiberto Belli, Vincenzo Mazzaferro, Jorgelina Coppa, Roberto Patuzzo, Mario R. Sertoli, Axel Hoos, Pramod K. Srivastava, Mario Santinami

Clin Cancer Res (2004) 10 (24): 8142–8146.

https://doi.org/10.1158/1078-0432.CCR-04-1194

Published: 28 December 2004

View article titled, Heat Shock Proteins and Their Use as Anticancer Vaccines

Journal Articles

5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications

Sandra Coral, Luca Sigalotti, Maresa Altomonte, Arne Engelsberg, Francesca Colizzi, Ilaria Cattarossi, Eugene Maraskovsky, Elke Jager, Barbara Seliger, Michele Maio

Clin Cancer Res (2002) 8 (8): 2690–2695.

Published: 01 August 2002

View article titled, 5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: <subtitle>Immunotherapeutic Implications</subtitle>

Journal Articles

Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model

Ester Fonsatti, Antti P. Jekunen, Kalevi J. A. Kairemo, Sandra Coral, Marjatta Snellman, Maria Rita Nicotra, Pier Giorgio Natali, Maresa Altomonte, Michele Maio

Clin Cancer Res (2000) 6 (5): 2037–2043.

Published: 01 May 2000

View article titled, Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model

NARROW

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF^V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF^V600-mutated Metastatic Melanoma

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Circulating CD4⁺ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma

Heat Shock Proteins and Their Use as Anticancer Vaccines

5-aza-2′-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications

Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only